Wogonoside induces apoptosis in human non-small cell lung cancer A549 cells by promoting mitochondria dysfunction

Area of Science:

• Oncology
• Pharmacology
• Cell Biology

Background:

• Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related mortality globally.
• Wogonoside has demonstrated anti-tumor properties in several human cancer types, but its efficacy against NSCLC is not well-established.
• Understanding novel therapeutic agents for NSCLC is crucial for improving patient outcomes.

Purpose of the Study:

• To investigate the anti-tumor effects of wogonoside on human non-small cell lung cancer (NSCLC) A549 cells.
• To elucidate the mechanisms underlying wogonoside's anti-cancer activity in NSCLC.
• To evaluate the therapeutic potential of wogonoside for NSCLC treatment.

Main Methods:

• In vitro studies using human NSCLC A549 cell lines to assess cell viability, cell cycle arrest, and apoptosis.
• In vivo studies involving intraperitoneal administration of wogonoside to athymic nude mice bearing A549 cell xenografts.
• Analysis of mitochondrial membrane potential and cytochrome c release in treated cells.
• Investigation of the involvement of AMPK/mTOR signaling pathways.

Main Results:

• Wogonoside significantly inhibited A549 cell viability.
• Wogonoside induced cell cycle arrest and promoted apoptosis in NSCLC cells.
• In vivo administration of wogonoside suppressed the growth of A549 xenografts.
• Wogonoside treatment disrupted mitochondrial membrane potential and led to cytochrome c release.
• The AMPK/mTOR signaling pathway was implicated in wogonoside's anti-NSCLC effects.

Conclusions:

• Wogonoside exhibits significant anti-tumor activity against human non-small cell lung cancer cells in vitro and in vivo.
• The anti-cancer mechanisms involve the induction of apoptosis and cell cycle arrest, potentially mediated by mitochondrial dysfunction.
• Wogonoside, possibly through the AMPK/mTOR pathway, represents a promising therapeutic candidate for NSCLC treatment.